---
title: "12 Health Care Stocks Moving In Monday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293930921.md"
description: "In Monday's pre-market session, several healthcare stocks showed significant movement. Gainers included Matinas BioPharma (up 59.7%), Forte Biosciences (up 39.61%), and First Tracks (up 34.43%). Conversely, major losers were MapLight Therapeutics (down 54.7%) and Capricor Therapeutics (down 41.12%). Other notable decliners included IM Cannabis and Profusa."
datetime: "2026-07-27T12:05:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293930921.md)
  - [en](https://longbridge.com/en/news/293930921.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293930921.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Monday's Pre-Market Session

### Gainers

-   **Matinas BioPharma Hldgs** (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million.
-   **Forte Biosciences** (NASDAQ:FBRX) stock rose 39.61% to $76.48. The market value of their outstanding shares is at $1.1 billion.
-   **First Tracks** (NASDAQ:TRAX) shares increased by 34.43% to $47.75. The market value of their outstanding shares is at $1.2 billion.
-   **Catheter Precision** (AMEX:VTAK) stock rose 26.87% to $0.33.
-   **Gossamer Bio** (NASDAQ:GOSS) stock increased by 23.38% to $0.17. The company's market cap stands at $66.4 million.
-   **China SXT Pharmaceuticals** (NASDAQ:SXTC) shares rose 18.65% to $0.08. The company's market cap stands at $2.4 million.

### Losers

-   **MapLight Therapeutics** (NASDAQ:MPLT) shares declined by 54.7% to $16.56 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
-   **Capricor Therapeutics** (NASDAQ:CAPR) shares decreased by 41.12% to $11.6. The company's market cap stands at $1.1 billion.
-   **IM Cannabis** (NASDAQ:IMCC) shares decreased by 17.29% to $0.1. The market value of their outstanding shares is at $1.0 million.
-   **Profusa** (NASDAQ:PFSA) stock fell 15.79% to $1.44.
-   **Bio Green Med Solution** (NASDAQ:BGMS) shares fell 12.57% to $0.8. The market value of their outstanding shares is at $5.0 million.
-   **CytoMed Therapeutics** (NASDAQ:GDTC) shares fell 12.12% to $0.87. The company's market cap stands at $11.7 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [MPLT.US](https://longbridge.com/en/quote/MPLT.US.md)
- [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md)
- [FBRX.US](https://longbridge.com/en/quote/FBRX.US.md)
- [TRAX.US](https://longbridge.com/en/quote/TRAX.US.md)
- [CAPR.US](https://longbridge.com/en/quote/CAPR.US.md)
- [PFSA.US](https://longbridge.com/en/quote/PFSA.US.md)
- [IMCC.US](https://longbridge.com/en/quote/IMCC.US.md)
- [VTAK.US](https://longbridge.com/en/quote/VTAK.US.md)
- [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md)
- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)
- [BGMS.US](https://longbridge.com/en/quote/BGMS.US.md)
- [GDTC.US](https://longbridge.com/en/quote/GDTC.US.md)
- [34962G208.US](https://longbridge.com/en/quote/34962G208.US.md)
- [NVACW.US](https://longbridge.com/en/quote/NVACW.US.md)
- [BGMSP.US](https://longbridge.com/en/quote/BGMSP.US.md)

## Related News & Research

- [Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares](https://longbridge.com/en/news/296276892.md)
- [MapLight Q2 FY26 net loss widens to $60.19 million; R&D expenses rise to $53.44 million](https://longbridge.com/en/news/295839597.md)
- [Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders | CAPR Stock News](https://longbridge.com/en/news/296614024.md)
- [Activist Investor Sounds Alarm on Capricor’s Cash Burn](https://longbridge.com/en/news/296644057.md)
- [Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns](https://longbridge.com/en/news/296098763.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**